BioScience Health Innovations I (BHIC) Fair Value 2026

BHIC · Pharmaceutical Retailers ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

6.8 /10

32 fundamental signals · 5 models active

Value Trap Risk

LOW (25/100)

Quick Summary — As of 2026-08-27, BioScience Health Innovations I (BHIC) trades at $4.98, versus a $0.34 median fair value across its 5 active models — 93.3% below the current price. QOC: 6.8/10. Value Trap Risk: 25/100 (LOW). 5/13 models active. Within that set, the Bayesian DCF component alone returns $0.12.

Key Facts

Ticker
BHIC
Price
$4.98
Quality Score
6.8/10
Value Trap Risk
25/100
Models Active
5/13
Last Updated
Strength: 5 independent models provide multi-angle coverage
Risk: Majority of models suggest overvaluation

Is BioScience Health Innovations I (BHIC) Undervalued or Overvalued in 2026?

According to CirclFi’s 5-model valuation engine, BioScience Health Innovations I (BHIC) appears overvalued as of : the median of 5 independent fair value estimates is $0.34, 93.3% below the current price of $4.98. Estimates range from $0.09 to $1.12. BHIC scores 6.8/10 on fundamental quality and 25/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.7% versus its own 13-model consensus, across 3,801 rated companies as of 2026-08-27. BHIC’s -93.3% gap is wider than that market norm. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy BioScience Health Innovations I Stock in 2026? →

What Fair Value Does Each Model Give BHIC?

5 Intrinsic Value Models vs. Current Price ($4.98)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · High Conviction
 $0.12 -97.6%
Ensemble · Low Conviction
 $0.34 -93.3%
Unlock the Full Matrix

Access 3 additional models including EROIC Spread, First Chicago, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 5 Models →

Cancel anytime · No contracts · Instant access

What Is BHIC's Fair Value Range?

Spread across 5 independent models · $0.09 to $1.12

CirclFi's 5 active models place BioScience Health Innovations I (BHIC) between $0.09 and $1.12 per share, a spread of 307% of the median. The median of that range — $0.34 — is the fair value CirclFi publishes for BHIC, against a current price of $4.98.

Low · RCMH-DCFHigh · First Chicago
$0.09median $0.34$1.12
Where the range comes from
Most bearish modelRCMH-DCF$0.09
Most bullish modelFirst Chicago$1.12
Model agreement0 bullish · 5 bearishwide

A band this wide is itself the finding. When independent methods land far apart, they are reading a business whose value depends heavily on which lens you apply — volatile earnings, heavy reinvestment, or an asset base that cash-flow and asset-based methods score differently. That disagreement is information: it says the choice of method matters more than usual for BHIC. Treat the median as one reading among several and compare the individual models below before acting.

Every figure above is one model's standalone output on BHIC, not a CirclFi price target. How each model works →

What Is BioScience Health Innovations I (BHIC) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, BioScience Health Innovations I's intrinsic value is estimated at $0.34. Trading at its current price of $4.98, the valuation engine raises significant caution: 5 of 5 models flag downside risk, projecting a median implied return of -93.3%.

What Do the Models Say About BHIC?

5 of 13 models are currently active for BHIC. All 5 active models suggest the stock trades above fair value. Taken together, their median fair value for BHIC is $0.34 — the figure CirclFi publishes as this stock's fair value. One component of that median, the Bayesian DCF, returns $0.12 on its own, implying -97.6% downside from the current price. See which stocks rank higher →

How Does BHIC Rank in Pharmaceutical Retailers?

Among 9 Pharmaceutical Retailers stocks, BHIC ranks #1 by Quality of Company score. CirclFi's QOC score of 6.8/10 evaluates 32 fundamental signals. A score of 6.8 indicates above-average quality.

BioScience Health Innovations I's positioning within the Pharmaceutical Retailers segment means that clinical trial success rate plays an outsized role in fundamental analysis. The sector's unique characteristics — including late-stage pipeline catalysts — shape both the opportunity set and risk profile.

Is BHIC a Value Trap?

CirclFi's Value Trap algorithm assigns BHIC a score of 25/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

5 of 13 models are active for BioScience Health Innovations I. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, BioScience Health Innovations I earns a quality score of 6.8/10. This respectable rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.

Models cluster within a tight range (+20.7% spread), increasing conviction. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every BHIC valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across BHIC's 5 active models, average confidence is 32%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy BioScience Health Innovations I Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Pharmaceutical Retailers Stocks Should You Also Analyze?

8 related Pharmaceutical Retailers stocks with 13-model coverage

PETSPetMed Express, Inc.QOC 6.2HITIHigh Tide Inc.QOC 5.8SHFHScientist Home Future Health LimitedQOC 5.6DHTIDalrada Technology Group Inc.QOC 5.4SCNXScienture Holdings, Inc.QOC 5.2PMHSPolomar Health Services, Inc.QOC 5.2POMPomdoctor LimitedQOC 4.9RDGTRidgetech, Inc.QOC 1.8

Read investment analysis: PETS · HITI · SHFH · DHTI · SCNX · PMHS · POM · RDGT

Which Other Stocks Have a Similar Quality Score to BHIC?

7 companies across all industries closest to BHIC’s Quality of Company score of 6.8/10.

BGBunge Global SAQOC 6.8OIO-I Glass, Inc.QOC 6.8MNTNMNTN, Inc.QOC 6.8CIZNCitizens Holding CompanyQOC 6.8FDMT4D Molecular Therapeutics, Inc.QOC 6.8ICCCImmuCell CorporationQOC 6.8NVDANVIDIA CorporationQOC 10.0

Read investment analysis: BG · OI · MNTN · CIZN · FDMT · ICCC · NVDA

What Else Do Investors Ask About BioScience Health Innovations I’s Valuation?

What is BioScience Health Innovations I's intrinsic value in 2026?

CirclFi puts BioScience Health Innovations I (BHIC)'s intrinsic value at $0.34 — the median of 5 independent model estimates as of 2026-08-27, ranging from $0.09 to $1.12. One component of that median, the Bayesian DCF, runs 10,000 Monte Carlo simulations with jump-diffusion and returns $0.12 on its own. The Quality of Company score is 6.8/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is BHIC overvalued or undervalued right now?

At $4.98, 0 of 5 active models suggest BHIC may be undervalued, while 5 indicate potential overvaluation. The median of all 5 fair value estimates is $0.34, 93.3% below the current price of $4.98 — a consensus view that BHIC is overvalued. The assessment depends on which methodology best fits BioScience Health Innovations I's business model in Pharmaceutical Retailers.

What does a Quality of Company score of 6.8 mean for BHIC?

BioScience Health Innovations I's QOC of 6.8/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on BHIC?

CirclFi analyzes BHIC with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 5 of 13 are active for this stock. Read the full methodology →

Which valuation models are most bullish and most bearish on BHIC?

Of the 5 models currently active on BHIC, First Chicago is the most bullish at $1.12 per share, and RCMH-DCF is the most bearish at $0.09. CirclFi's published fair value for BHIC is the median of that range, $0.34, not either extreme. The gap between the two ends equals 307% of the median — a wide spread, meaning the methods genuinely disagree and the median should carry less weight. Browse stocks by value-trap risk →

Is BHIC a value trap in 2026?

BioScience Health Innovations I's Value Trap score is 25/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap.

Cite this analysis — “According to CirclFi’s 5-model valuation engine, BioScience Health Innovations I (BHIC) has a median fair value of $0.34 — 93.3% below the current price of $4.98 — as of 2026-08-27.” Source: circlfi.com/stock/BHIC/ · Methodology
Primary sources for this BHIC valuation
  • Financial statements: BioScience Health Innovations I 10-K and 10-Q filings on SEC EDGAR (CIK 0001784440) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for BHIC as of ; valuations recomputed .

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 5 mathematical frameworks give you clarity on BHIC.

Unlock All 5 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access

3 models hidden for BHIC Unlock All 5 — $39/mo